Lastly, diverse research lines are currently open in this field, leading to the identification of promising unconventional therapeutic targets such as miR-1298 that inhibits tumor growth in KRAS-driven tumors [153] or the Inhibitor of Differention-1 (Id1) [154] that may have chemopreventive and therapeutic efficacy in KRAS-mutated lung tumors. Here, KRAS is linked to neoplasm.